

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated Thursday, September 1, 2022 (the “**Prospectus**”) issued by Dingdang Health Technology Group Ltd. (the “**Company**”). This announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong).

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for any securities of the Company. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Offer Shares.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or in any other jurisdiction. The Offer Shares have not been and will not be registered under the United States Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”) or securities law of any state or other jurisdiction of the United States and may not be offered, sold, pledged or transferred within the United States, except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act. There will be no public offer of the Offer Shares in the United States. The Offer Shares are being offered and sold (1) solely to qualified institutional buyers as defined in Rule 144A under the U.S. Securities Act pursuant to an exemption from registration under the U.S. Securities Act and (2) outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.



DINGDANG HEALTH TECHNOLOGY GROUP LTD.

叮噹健康科技集團有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 9886)

STABILIZING ACTIONS, END OF STABILIZATION PERIOD AND LAPSE OF THE OVER-ALLOTMENT OPTION

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

The Company announces that the stabilization period in connection with the Global Offering ended on Thursday, October 6, 2022, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering. Further information in relation to the stabilization actions undertaken by the Stabilizing Manager, or any person acting for it, during the stabilization period, is set out below.

LAPSE OF THE OVER-ALLOTMENT OPTION

The Company further announces that the Over-allotment Option had not been exercised by the Joint Global Coordinators (on behalf of the International Underwriters) during the stabilization period and lapsed on Thursday, October 6, 2022. Accordingly, no Shares were or will be issued under the Over-allotment Option.

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

Pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), the Company announces that the stabilization period in connection with the Global Offering ended on Thursday, October 6, 2022, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering.

The stabilizing actions undertaken by the Stabilizing Manager, or any person acting for it, during the stabilization period are set out below:

- (i) over-allocation of an aggregate of 5,030,500 Shares under the International Offering, representing approximately 15% of the total number of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option; and
- (ii) successive purchases of an aggregate of 5,030,500 Shares in the price range of HK\$11.98 to HK\$12.00 per Share (exclusive of brokerage of 1.0%, SFC transaction levy of 0.0027%, FRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.005%) on the market during the stabilization period, representing approximately 15.0% of the total number of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option to facilitate the delivery to the cornerstone investor which has agreed to a delayed delivery of Shares subscribed by it under its cornerstone investment agreement. The last purchase made by the Stabilizing Manager or any person acting for it, on the market during the course of the stabilization period was on Thursday, September 29, 2022 at the price of HK\$12.00 per Share (exclusive of brokerage of 1.0%, SFC transaction levy of 0.0027%, FRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.005%).

LAPSE OF THE OVER-ALLOTMENT OPTION

The Company further announces that the Over-allotment Option had not been exercised by the Joint Global Coordinators (on behalf of the International Underwriters) during the stabilization period and lapsed on Thursday, October 6, 2022. Accordingly, no Shares were or will be issued under the Over-allotment Option.

PUBLIC FLOAT

The Directors confirm that, immediately after the end of the stabilization period, the issued share capital of the Company which are held by the public continues to satisfy the minimum percentage requirement of 25.0% as prescribed in Rule 8.08(1) of the Listing Rules.

By order of the Board
DINGDANG HEALTH TECHNOLOGY GROUP LTD.
YANG WENLONG
Chairman

Hong Kong, October 6, 2022

As of the date of this announcement, the executive Directors are Mr. YANG Wenlong, Mr. XU Ning, Mr. YU Lei and Mr. YU Qinglong, the non-executive Directors are Ms. CAI Li and Ms. LIAN Suping, and the independent non-executive Directors are Mr. ZHANG Shouchuan, Mr. FAN Zhenhong and Mr. JIANG Shan.